87 related articles for article (PubMed ID: 22032800)
1. Risk of early recurrent fetal loss and levels of thrombin-activatable fibrinolysis inhibitor.
Legnani C; Bovara M; Valdrè L; Cosmi B; Caniato A; Palareti G
Thromb Res; 2012 Aug; 130(2):237-41. PubMed ID: 22032800
[TBL] [Abstract][Full Text] [Related]
2. +1040 C/T polymorphism in coding region of thrombin-activatable fibrinolysis inhibitor gene and the risk of idiopathic recurrent fetal loss.
Pruner I; Djordjevic V; Miljic P; Kovac M; Antonijevic N; Rakicevic L; Radojkovic D
Blood Coagul Fibrinolysis; 2010 Oct; 21(7):679-82. PubMed ID: 20729722
[TBL] [Abstract][Full Text] [Related]
3. Thrombin-activatable fibrinolysis inhibitor polymorphisms and recurrent pregnancy loss.
Masini S; Ticconi C; Gravina P; Tomassini M; Pietropolli A; Forte V; Federici G; Piccione E; Bernardini S
Fertil Steril; 2009 Aug; 92(2):694-702. PubMed ID: 18774564
[TBL] [Abstract][Full Text] [Related]
4. Thrombin activatable fibrinolysis inhibitor and clot lysis time in women with recurrent miscarriage associated with the antiphospholipid syndrome.
Martínez-Zamora MA; Creus M; Tassies D; Bové A; Reverter JC; Carmona F; Balasch J
Fertil Steril; 2010 Nov; 94(6):2437-40. PubMed ID: 20378110
[TBL] [Abstract][Full Text] [Related]
5. Thrombin-activatable fibrinolysis inhibitor (TAFI) antigen and activity assay in patients with primary hypothyroidism.
Ermantas N; Guldiken S; Demir M; Tugrul A
Clin Appl Thromb Hemost; 2010 Oct; 16(5):568-73. PubMed ID: 19959491
[TBL] [Abstract][Full Text] [Related]
6. Levels of thrombin activatable fibrinolysis inhibitor in gestational diabetes mellitus.
Gumus II; Kargili A; Karakurt F; Kasapoglu B; Derbent A; Kaygusuz I; Koca C; Sevgili S
Gynecol Endocrinol; 2013 Apr; 29(4):327-30. PubMed ID: 23327722
[TBL] [Abstract][Full Text] [Related]
7. Changes in activity of plasma thrombin activatable fibrinolysis inhibitor in pregnancy.
Watanabe T; Minakami H; Sakata Y; Matsubara S; Sato I; Suzuki M
Gynecol Obstet Invest; 2004; 58(1):19-21. PubMed ID: 15004439
[TBL] [Abstract][Full Text] [Related]
8. Association between genotype and plasma levels of thrombin-activated fibrinolysis inhibitor (TAFI) in the development of preeclampsia.
Acosta-Tejeda M; Baptista-González H; Rosenfeld-Mann F; Trueba-Gómez R; García-Latorre E
Thromb Res; 2011 Oct; 128(4):e39-42. PubMed ID: 21708401
[TBL] [Abstract][Full Text] [Related]
9. Serum thrombin activatable fibrinolysis inhibitor levels in patients with newly diagnosed multiple myeloma.
Balcik OS; Albayrak M; Uyar ME; Dagdas S; Yokus O; Ceran F; Cipil H; Kosar A; Ozet G
Blood Coagul Fibrinolysis; 2011 Jun; 22(4):260-3. PubMed ID: 21297448
[TBL] [Abstract][Full Text] [Related]
10. Assessment of thrombin-activatable fibrinolysis inhibitor (TAFI) plasma levels in inflammatory bowel diseases.
Saibeni S; Bottasso B; Spina L; Bajetta M; Danese S; Gasbarrini A; de Franchis R; Vecchi M
Am J Gastroenterol; 2004 Oct; 99(10):1966-70. PubMed ID: 15447757
[TBL] [Abstract][Full Text] [Related]
11. Gestational diabetes has no additional effect on plasma thrombin-activatable fibrinolysis inhibitor antigen levels beyond pregnancy.
Akinci B; Demir T; Saygili S; Yener S; Alacacioglu I; Saygili F; Bayraktar F; Yesil S
Diabetes Res Clin Pract; 2008 Jul; 81(1):93-6. PubMed ID: 18406001
[TBL] [Abstract][Full Text] [Related]
12. Plasma thrombin-activatable fibrinolysis inhibitor levels are not associated with glucose intolerance and subclinical atherosclerosis in women with previous gestational diabetes.
Akinci B; Celtik A; Yener S; Genc S; Tunali S; Yuksel F; Ozcan MA; Secil M; Yesil S
Clin Appl Thromb Hemost; 2011; 17(6):E224-30. PubMed ID: 21406417
[TBL] [Abstract][Full Text] [Related]
13. Thrombin activatable fibrinolysis inhibitor in Behçet's disease.
Donmez A; Aksu K; Celik HA; Keser G; Cagirgan S; Omay SB; Inal V; Aydin HH; Tombuloglu M; Doganavsargil E
Thromb Res; 2005; 115(4):287-92. PubMed ID: 15668188
[TBL] [Abstract][Full Text] [Related]
14. Decrements in the thrombin activatable fibrinolysis inhibitor (TAFI) levels in association with orlistat treatment in obesity.
Guven GS; Kiliçaslan A; Oz SG; Haznedaroglu IC; Kirazli S; Aslan D; Sözen T
Clin Appl Thromb Hemost; 2006 Jul; 12(3):364-8. PubMed ID: 16959692
[TBL] [Abstract][Full Text] [Related]
15. Plasma levels of thrombin activatable fibrinolysis inhibitor in normal and preeclamptic pregnant women.
Alacacioğlu I; Ozcan MA; Alacacioğlu A; Polat M; Yüksel F; Demirkan F; Pişkin O; Ozgenç Y; Ozsan HG; Undar B
Thromb Res; 2004; 114(3):155-9. PubMed ID: 15342211
[TBL] [Abstract][Full Text] [Related]
16. Assessment of the role of thrombin activatable fibrinolysis inhibitor in retinal vein occlusion.
Gumus K; Kadayifcilar S; Eldem B; Ozcebe O
Retina; 2007 Jun; 27(5):578-83. PubMed ID: 17558319
[TBL] [Abstract][Full Text] [Related]
17. Thrombin-activatable fibrinolysis inhibitor and cardiovascular risk factors in polycystic ovary syndrome.
Erdoğan M; Karadeniz M; Alper GE; Tamsel S; Uluer H; Cağlayan O; Saygili F; Yilmaz C
Exp Clin Endocrinol Diabetes; 2008 Mar; 116(3):143-7. PubMed ID: 18350479
[TBL] [Abstract][Full Text] [Related]
18. Association of functional thrombin-activatable fibrinolysis inhibitor (TAFI) with conventional cardiovascular risk factors and its correlation with other hemostatic factors in a Spanish population.
Santamaría A; Borrell M; Oliver A; Ortín R; Forner R; Coll I; Mateo J; Souto JC; Fontcuberta J
Am J Hematol; 2004 Aug; 76(4):348-52. PubMed ID: 15282667
[TBL] [Abstract][Full Text] [Related]
19. [Thrombin activatable fibrinolysis inhibitor (TAFI) in allergic asthma patients].
Kemona-Chetnik I; Kowal K; Kucharewicz I; Pampuch A; Bodzenta-Lukaszyk A
Przegl Lek; 2006; 63(12):1281-5. PubMed ID: 17642140
[TBL] [Abstract][Full Text] [Related]
20. Deficiency of thrombin activatable fibrinolysis inhibitor in cirrhosis is associated with increased plasma fibrinolysis.
Colucci M; Binetti BM; Branca MG; Clerici C; Morelli A; Semeraro N; Gresele P
Hepatology; 2003 Jul; 38(1):230-7. PubMed ID: 12830006
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
